Squarepoint Ops LLC Takes $161,000 Position in Veru Inc. (NASDAQ:VERU)

Squarepoint Ops LLC purchased a new stake in Veru Inc. (NASDAQ:VERU) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 191,519 shares of the company’s stock, valued at approximately $161,000. Squarepoint Ops LLC owned approximately 0.13% of Veru as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of VERU. 180 Wealth Advisors LLC bought a new stake in shares of Veru in the 1st quarter valued at about $120,000. Choreo LLC acquired a new stake in Veru in the 1st quarter worth approximately $64,000. Alpine Global Management LLC boosted its stake in Veru by 21.0% in the 1st quarter. Alpine Global Management LLC now owns 710,000 shares of the company’s stock worth $497,000 after purchasing an additional 122,999 shares in the last quarter. Ikarian Capital LLC acquired a new stake in Veru in the 1st quarter worth approximately $663,000. Finally, Cetera Advisors LLC acquired a new stake in Veru in the 1st quarter worth approximately $33,000. 47.16% of the stock is currently owned by institutional investors.

Veru Stock Up 5.0 %

VERU stock opened at $0.87 on Monday. The firm has a 50 day moving average of $0.82 and a 200 day moving average of $0.99. The stock has a market capitalization of $126.78 million, a PE ratio of -2.55 and a beta of -0.49. Veru Inc. has a 52 week low of $0.36 and a 52 week high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. The business had revenue of $3.95 million for the quarter, compared to analyst estimates of $3.50 million. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. On average, equities research analysts expect that Veru Inc. will post -0.3 earnings per share for the current year.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.